KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $686.0 million.

  • Teva Pharmaceutical Industries' Income towards Parent Company rose 34326.24% to $686.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $686.0 million, marking a year-over-year increase of 34326.24%. This contributed to the annual value of $1.4 billion for FY2025, which is 17112.35% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Income towards Parent Company stood at $686.0 million, which was up 34326.24% from $428.0 million recorded in Q3 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Income towards Parent Company peaked at $686.0 million during Q4 2025, and registered a low of -$2.4 billion during Q4 2023.
  • Its 5-year average for Income towards Parent Company is -$747.3 million, with a median of -$744.5 million in 2021.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Income towards Parent Company plummeted by 11153.42% in 2022 and then surged by 34326.24% in 2025.
  • Teva Pharmaceutical Industries' Income towards Parent Company (Quarter) stood at -$1.1 billion in 2021, then tumbled by 90.51% to -$2.1 billion in 2022, then fell by 13.53% to -$2.4 billion in 2023, then skyrocketed by 88.33% to -$282.0 million in 2024, then soared by 343.26% to $686.0 million in 2025.
  • Its Income towards Parent Company stands at $686.0 million for Q4 2025, versus $428.0 million for Q3 2025 and $274.0 million for Q2 2025.